Abstract
Some of the antagonists of growth hormone-releasing hormone (GHRH) are able to inhibit the growth of various experimental human cancers. The antitumor effects of first antagonists seemed to be dependent mainly on the disruption of pituitary secretion of growth hormone (GH), followed by the reduction in the levels of circulating insulin-like growth factor (IGF)-1, an important growth factor for cancer cells. It seems obvious, that growth hormone deficiency (GHD) induced by GHRH antagonists with all its complications, could limit the beneficial effects of GHRH antagonists therapy, and decrease patients quality of life. The discovery of local autocrine/paracrine production of GHRH and other related growth factors in many tumoral tissues, in combination with the wide expression of GHRH receptors on cancer cells, directed the research to the synthesis of more potent GHRH antagonists. These compounds exert strong inhibitory effects directly on tumor growth, with scarce endocrine action. The receptor-mediated mechanisms comprise complex and still not completely understood effects on intracellular signaling pathways that are strictly related to human tumorigenesis. This review summarizes recent patents and latest observations on the antineoplastic role of GHRH antagonists in human tumors with emphasis on potential therapeutic applications in clinical oncology.
Keywords: Cancer therapy, GHRH, GHRH antagonists, IGF-I, IGF-II, antitumor effects, pituitary secretion, oncology, intracellular signaling pathways, tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery
Title: Antineoplastic Action of Growth Hormone-Releasing Hormone (GHRH) Antagonists
Volume: 7 Issue: 1
Author(s): Agnieszka Siejka, Hanna Lawnicka, Gabriela Melen-Mucha, Ewelina Motylewska, Jan Komorowski and Henryk Stepien
Affiliation:
Keywords: Cancer therapy, GHRH, GHRH antagonists, IGF-I, IGF-II, antitumor effects, pituitary secretion, oncology, intracellular signaling pathways, tumorigenesis
Abstract: Some of the antagonists of growth hormone-releasing hormone (GHRH) are able to inhibit the growth of various experimental human cancers. The antitumor effects of first antagonists seemed to be dependent mainly on the disruption of pituitary secretion of growth hormone (GH), followed by the reduction in the levels of circulating insulin-like growth factor (IGF)-1, an important growth factor for cancer cells. It seems obvious, that growth hormone deficiency (GHD) induced by GHRH antagonists with all its complications, could limit the beneficial effects of GHRH antagonists therapy, and decrease patients quality of life. The discovery of local autocrine/paracrine production of GHRH and other related growth factors in many tumoral tissues, in combination with the wide expression of GHRH receptors on cancer cells, directed the research to the synthesis of more potent GHRH antagonists. These compounds exert strong inhibitory effects directly on tumor growth, with scarce endocrine action. The receptor-mediated mechanisms comprise complex and still not completely understood effects on intracellular signaling pathways that are strictly related to human tumorigenesis. This review summarizes recent patents and latest observations on the antineoplastic role of GHRH antagonists in human tumors with emphasis on potential therapeutic applications in clinical oncology.
Export Options
About this article
Cite this article as:
Siejka Agnieszka, Lawnicka Hanna, Melen-Mucha Gabriela, Motylewska Ewelina, Komorowski Jan and Stepien Henryk, Antineoplastic Action of Growth Hormone-Releasing Hormone (GHRH) Antagonists, Recent Patents on Anti-Cancer Drug Discovery 2012; 7 (1) . https://dx.doi.org/10.2174/157489212798358010
DOI https://dx.doi.org/10.2174/157489212798358010 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [ Hot Topic:New Frontiers in Female Reproduction and Fertility (Executive Guest Editor: Sandra Cecconi)]
Current Pharmaceutical Design Infertility, Pregnancy Loss and Adverse Birth Outcomes in Relation to Maternal Secondhand Tobacco Smoke Exposure
Current Women`s Health Reviews Kinase Phosphorylation-based Mechanisms of PARP Inhibitor Resistance During Synthetic Lethal Oncotherapy
Current Signal Transduction Therapy Current and Future Development of Estrogen Receptor Ligands: Applications in Estrogen-Related Cancers
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Design and Synthesis of Tetrahydroisoquinoline Derivatives as Anti-Angiogenesis and Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Achievements and Challenges of Proteomics in the Study of Rheumatoid Arthritis
Current Topics in Medicinal Chemistry The CCL2/CCR2 Axis in the Pathogenesis of HIV-1 Infection: A New Cellular Target for Therapy?
Current Drug Targets Hormone Replacement Therapy and Stroke
Current Vascular Pharmacology Plants vs. Cancer: A Review on Natural Phytochemicals in Preventing and Treating Cancers and Their Druggability
Anti-Cancer Agents in Medicinal Chemistry Fibroblast Growth Factor-2, Bone Homeostasis and Fracture Repair
Current Pharmaceutical Design The Extracellular Matrix of Blood Vessels
Current Pharmaceutical Design Bacterial Biotransformation and Anticancer Activities of Betulin against A549, HepG2 and 5RP7 Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry The Anti-cancer Actions of Vitamin D
Anti-Cancer Agents in Medicinal Chemistry Women’s Ginseng (Angelica sinensis): An Ethnopharmacological Dossier
Current Traditional Medicine Diffusion-Weighted Imaging in Abdominal Oncology
Current Medical Imaging Histone Methyltransferase Inhibitors: Novel Epigenetic Agents for Cancer Treatment
Current Medicinal Chemistry Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research From the Sea to Anticancer Therapy
Current Medicinal Chemistry Anticipation in Lynch Syndrome: Where We Are Where We Go
Current Genomics Clinical Development of Microbicides for the Prevention of HIV Infection
Current Pharmaceutical Design